UY27595A1 - Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear - Google Patents

Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear

Info

Publication number
UY27595A1
UY27595A1 UY27595A UY27595A UY27595A1 UY 27595 A1 UY27595 A1 UY 27595A1 UY 27595 A UY27595 A UY 27595A UY 27595 A UY27595 A UY 27595A UY 27595 A1 UY27595 A1 UY 27595A1
Authority
UY
Uruguay
Prior art keywords
hormone receptor
fusioned
modulators
heterocyclic
analog
Prior art date
Application number
UY27595A
Other languages
English (en)
Inventor
Dacia A Pickering
Aberra Fura
Ramesh N Patel
Soren Giese
Wenying Li
Mark E Salvati
James Aaron Balog
Hai-Yun Xiao
Ronald L Hanson
Toomas Mitt
Jacques R Corte
Steven H Spergel
Richard A Raj Misra
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of UY27595A1 publication Critical patent/UY27595A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
    • C07D495/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/08—Antiseborrheics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Addiction (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Compuestos cíclicos fusionados, métodos de uso de tales compuestos en el tratamiento de condiciones asociadas con el receptor de la hormona nuclear tal como el cáncer y padecimientos inmunes, y composiciones farmacéuticas que contienen tales compuestos
UY27595A 2001-12-19 2002-12-19 Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear UY27595A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2511601A 2001-12-19 2001-12-19

Publications (1)

Publication Number Publication Date
UY27595A1 true UY27595A1 (es) 2003-07-31

Family

ID=27609007

Family Applications (1)

Application Number Title Priority Date Filing Date
UY27595A UY27595A1 (es) 2001-12-19 2002-12-19 Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear

Country Status (31)

Country Link
EP (1) EP1458723B1 (es)
JP (1) JP2005523257A (es)
KR (1) KR20040086248A (es)
CN (1) CN1589271A (es)
AR (1) AR037950A1 (es)
AT (1) ATE411319T1 (es)
AU (1) AU2002361785B2 (es)
BR (1) BR0215281A (es)
CA (1) CA2471342A1 (es)
CO (1) CO5640082A2 (es)
DE (1) DE60229435D1 (es)
DK (1) DK1458723T3 (es)
ES (1) ES2314127T3 (es)
GE (1) GEP20063817B (es)
HR (1) HRP20040567A2 (es)
HU (1) HUP0402554A3 (es)
IL (1) IL162547A0 (es)
IS (1) IS7324A (es)
MX (1) MXPA04005876A (es)
NO (1) NO20043068L (es)
NZ (1) NZ533471A (es)
PL (1) PL370904A1 (es)
PT (1) PT1458723E (es)
RU (1) RU2330038C2 (es)
SI (1) SI1458723T1 (es)
TW (1) TWI263640B (es)
UA (1) UA78265C2 (es)
UY (1) UY27595A1 (es)
WO (1) WO2003062241A1 (es)
YU (1) YU53604A (es)
ZA (1) ZA200404812B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202264B2 (en) 2003-01-31 2007-04-10 Isis Pharmaceuticals, Inc. Supports for oligomer synthesis
FR2860793A1 (fr) * 2003-10-14 2005-04-15 Entomed Composes derives de norcantharidine, leurs procedes de preparation, les compositions les contenant et leurs utilisations
EP1692139B1 (en) * 2003-11-13 2013-02-13 Isis Pharmaceuticals, Inc. 5,6 -dihydroxy-isoindole derivatives as linkers for oligomer solid phase synthesis
US7569689B2 (en) 2004-01-16 2009-08-04 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7253283B2 (en) 2004-01-16 2007-08-07 Bristol-Myers Squibb Company Tricyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7326728B2 (en) 2004-01-16 2008-02-05 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κβ activity and use thereof
US7625921B2 (en) 2004-01-16 2009-12-01 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7605264B2 (en) 2004-01-16 2009-10-20 Bristol-Myers Squibb Company Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7273881B2 (en) 2004-01-16 2007-09-25 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP4880583B2 (ja) * 2004-03-17 2012-02-22 ファイザー・プロダクツ・インク 新規なベンジル（ベンジリデン）−ラクタム誘導体
US7411071B2 (en) 2005-01-13 2008-08-12 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7361654B2 (en) 2005-01-13 2008-04-22 Bristol-Myers Squibb Co. Substituted heteroaryl amide modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7317024B2 (en) 2005-01-13 2008-01-08 Bristol-Myers Squibb Co. Heterocyclic modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7642273B2 (en) 2005-01-13 2010-01-05 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
JP2009507843A (ja) * 2005-09-09 2009-02-26 シェーリング コーポレイション アザ縮合サイクリン依存性キナーゼ阻害剤
JP5275236B2 (ja) 2006-09-29 2013-08-28 スミスクライン ビーチャム コーポレーション 置換されたインドール化合物
WO2008157291A2 (en) * 2007-06-15 2008-12-24 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (3Aα, 4β, 5α, 7β, 7Aα)-4-(OCTAHYDRO-5-ETHYLSULFONAMIDO-4,7-DIMETHYL-1,3-DIOXO-4,7-EPOXY-2H-ISOINDOL-2-YL)-2-(TRIFLUOROMETHYL)BENZONITRILE AND METHOD OF PREPARATION
AU2010242307A1 (en) * 2009-04-30 2011-11-24 Sumitomo Chemical Company, Limited Thiophene derivative
WO2011007819A1 (ja) 2009-07-17 2011-01-20 塩野義製薬株式会社 ラクタムまたはベンゼンスルホンアミド化合物を含有する医薬
EP2475366A1 (en) 2009-09-11 2012-07-18 Bayer Pharma Aktiengesellschaft Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
ME03371B (me) 2010-01-14 2020-01-20 Novartis Ag Upotreba agensa za modifikovanje hormona adrenalina
WO2014111871A1 (en) 2013-01-17 2014-07-24 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
WO2014179564A1 (en) * 2013-05-01 2014-11-06 Vitae Pharmaceuticals, Inc. Thiazalopyrrolidine inhibitors of ror-gamma
JP6156074B2 (ja) * 2013-11-08 2017-07-05 住友化学株式会社 スクシンイミド化合物及びその用途
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
DK3372585T3 (da) * 2014-12-19 2022-05-30 Aragon Pharmaceuticals Inc Fremgangsmåde til fremstillingen af en diarylthiohydantoinforbindelse
JP6817962B2 (ja) * 2015-01-20 2021-01-20 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． ターゲティングされたアンドロゲン受容体分解のための化合物および方法
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
US10301261B2 (en) 2015-08-05 2019-05-28 Vitae Pharmaceuticals, Llc Substituted indoles as modulators of ROR-gamma
MA53943A (fr) 2015-11-20 2021-08-25 Vitae Pharmaceuticals Llc Modulateurs de ror-gamma
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
KR20190098204A (ko) 2016-12-29 2019-08-21 엔요 파마 항바이러스제로서의 티오펜 유도체
AU2018307919B2 (en) 2017-07-24 2022-12-01 Vitae Pharmaceuticals, Llc Inhibitors of RORϒ
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
JP2023518299A (ja) * 2020-03-20 2023-04-28 ユニバーシティー オブ サウザン カリフォルニア 小分子エナンチオマーによるアンドロゲン受容体調節
BR112022022669A2 (pt) 2020-05-08 2023-01-17 Halia Therapeutics Inc Inibidores de nek7 quinase
CN114848795B (zh) * 2021-02-03 2023-04-14 四川大学 RORa蛋白及其激动剂在制备抗衰老药物中的应用
WO2023154939A2 (en) * 2022-02-14 2023-08-17 The Johns Hopkins University Gcpii inhibition for the treatment of sarcopenia and aging
WO2024059200A1 (en) 2022-09-14 2024-03-21 Halia Therapeutics, Inc. Nek7 inhibitors

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320270A (en) * 1963-10-08 1967-05-16 Tri Kem Corp Certain 2-acylimidothiazole compounds
US3215597A (en) * 1963-10-30 1965-11-02 Dow Chemical Co Methods and compositions for use in animal husbandry
US3261845A (en) * 1964-07-14 1966-07-19 Dow Chemical Co N-phenyl derivatives of 3,6-epoxyhexahydrophthalimide
US4892943A (en) * 1985-10-16 1990-01-09 American Home Products Corporation Fused bicyclic imides with psychotropic activity
JPS63170383A (ja) * 1987-02-26 1988-07-14 Nippon Zeon Co Ltd 脂環式ジカルボン酸イミド化合物
ZA908641B (en) * 1989-10-27 1992-06-24 Du Pont (n-phthalimidoalkyl)piperidines
CN1103769C (zh) * 1996-10-25 2003-03-26 第一制药株式会社 三环胺衍生物
FR2764890B1 (fr) * 1997-06-24 1999-08-27 Adir Nouveaux derives chromeniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
AU1928800A (en) * 1998-12-22 2000-07-12 Eli Lilly And Company Substituted tricyclics
US6960474B2 (en) * 2000-06-28 2005-11-01 Bristol-Myers Squibb Company Method for the treatment of a condition remediable by administration of a selective androgen receptor modulator
CZ2003780A3 (cs) * 2000-09-19 2004-01-14 Bristol-Myers Squibb Company Kondenzované heterocyklické sukcinimidové sloučeniny a jejich analogy, modulátory funkce receptorů hormonů jádra

Also Published As

Publication number Publication date
CO5640082A2 (es) 2006-05-31
IL162547A0 (en) 2005-11-20
JP2005523257A (ja) 2005-08-04
EP1458723B1 (en) 2008-10-15
PT1458723E (pt) 2008-12-26
CA2471342A1 (en) 2003-07-31
RU2004122403A (ru) 2005-05-27
EP1458723A4 (en) 2005-12-21
ZA200404812B (en) 2005-08-26
WO2003062241A1 (en) 2003-07-31
MXPA04005876A (es) 2005-05-16
BR0215281A (pt) 2004-10-19
HUP0402554A2 (hu) 2005-03-29
DE60229435D1 (de) 2008-11-27
EP1458723A1 (en) 2004-09-22
HUP0402554A3 (en) 2009-01-28
DK1458723T3 (da) 2009-02-09
KR20040086248A (ko) 2004-10-08
YU53604A (sh) 2006-08-17
ATE411319T1 (de) 2008-10-15
TW200304810A (en) 2003-10-16
HRP20040567A2 (en) 2005-06-30
PL370904A1 (en) 2005-05-30
AU2002361785B2 (en) 2008-05-22
NO20043068L (no) 2004-09-08
CN1589271A (zh) 2005-03-02
ES2314127T3 (es) 2009-03-16
GEP20063817B (en) 2006-05-10
UA78265C2 (en) 2007-03-15
NZ533471A (en) 2007-05-31
SI1458723T1 (sl) 2009-02-28
IS7324A (is) 2004-06-18
TWI263640B (en) 2006-10-11
WO2003062241A8 (en) 2004-10-21
RU2330038C2 (ru) 2008-07-27
AR037950A1 (es) 2004-12-22

Similar Documents

Publication Publication Date Title
UY27595A1 (es) Compuestos de succinimida heterocíclicos, fusionados y analógos de los mismos, moduladores de la función del receptor de la hormona nuclear
UY26808A1 (es) Compuestos de succinimida heterocíclicos fusionados y análogos de los mismos, modulares de la función del receptor de hormona nuclear
AU2002364082A8 (en) Fused heterocyclic compounds and analogs thereof: modulators of nuclear hormone receptor function
PA8638701A1 (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos
AU2002359727A8 (en) Fused cyclic modulators of nuclear hormone receptor function
UY26482A1 (es) Bifenil sulfonamidas como antagonistas de receptores de angiotensina endotelina duales
CL2009000234A1 (es) Compuestos derivados de hetero-pentaciclo-fenilo fusionados; composicion farmaceutica; y uso en el tratamiento de la inflamacion, enfermedad autoinmune, trastornos oseos destructivos, transtorno proliferativo, infecciones bacterianas y virales, enfermedad neurodegenerativa. (divisional de solicitud n° 2004-0416).
HN1998000155A (es) Medicamentos
CL2010001160A1 (es) Compuestos derivados de 3,8-diazabiciclo[4.2.0]octano y 3,6-diazabiciclo[3.2.0]heptano; composicion farmaceutica; moduladores del reeptor de la orexina, utiles en el tratamiento del insomnio.
ECSP088324A (es) 2-amino-7,8-dihidro-6h-pirido[4,3-d]pirimidina-5-onas
NO20026167D0 (no) Kondenserte cykliske forbindelser som modulatorer av nukle¶r hormon reseptor funksjon
CL2021003228A1 (es) Compuestos tricíclicos y su uso
SV2008002856A (es) 2-amino-7, 8-dihidro-6h-pirido [4,3-d] pirimidina-5-onas
UY26809A1 (es) Moduladores cíclicos fusionados de función de receptor hormonal nuclear
ECSP024410A (es) Moduladores cilcicos fusionados de la funcion de receptores nucleares hormonales
EP1854798A3 (en) Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function
CR7442A (es) Derivados de benzimidazol 1-fenil-2- heteroaril- sustituidos, su uso para preparar medicamentos para el tratamiento de enfermedades inmunologicas
CL2011002318A1 (es) Compuestos derivados de tienopirimidindiona, moduladores trpa1; composicion farmaceutica que los comprende; y su uso en el tratamiento del dolor.
ECSP034500A (es) Guanidinobenzamidas novedosas
SV2006002164A (es) Moduladores del receptor de progesterona que comprenden derivados de pirrol-oxindol y sus usos ref. am101747
MX9301870A (es) Antagonistas receptores de angiotensina ii
AR061526A1 (es) Polipeptidos del factor de coagulacion ix modificados y uso de los mismos para tratamiento

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20140421